Guest: Dave Hallett

Cancer, called the “Emperor of All Maladies” has been a formidable adversary of mankind since time immemorial. With its multitude of forms and elusive nature, cancer presents a daunting challenge for drug discovery. However, AI offers a glimmer of hope. From lung and breast cancer to melanoma and leukemia, AI-driven drug discovery is harnessing the power of machine learning, deep learning, and predictive analytics, to target a diverse array of cancer types for more effective treatments.

Join us for a conversation with Dr. Dave Hallet, an  experienced drug hunter with over 20 years’ experience leading successful teams and collaborations for drug discovery. Dave is also the Chief Science Officer and the interim CEO at Exscientia, a publicly listed global drug discovery company headquartered in the UK.

Hosted by: Alexa Raad and Leslie Daigle.

Further reading:

• 
  
• NIH: Advances of Artificial Intelligence in Anti-Cancer Drug Design: A Review of the Past Decade
  
  
• AI is dreaming up drugs that no one has ever seen. Now we’ve got to see if they work
  
  
• Startups Are Using AI to Predict Responses to Cancer Drugs
  

The views and opinions expressed in this program are our own and may not reflect the views or positions of our employers.